{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:54:36Z","timestamp":1781646876094,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMW","doi-asserted-by":"publisher","award":["10510022110010"],"award-info":[{"award-number":["10510022110010"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","award":["WE.03-2024-06"],"award-info":[{"award-number":["WE.03-2024-06"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["949570"],"award-info":[{"award-number":["949570"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Traditionally, subgroups have been used to explore the effects of tau heterogeneity on cognition. However, categorization into rigid, exclusive subtypes, each with their own tau pattern, may overlook the fact that individual tau patterns are complex, and most individuals express features of multiple patterns. Mapping tau patterns in all their complexity has important clinical implications, as it may enable more accurate prognostication and support the development of personalized therapeutic strategies tailored to an individual\u2019s unique tau profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We applied a data-driven Bayesian model using Latent Dirichlet Allocation (LDA) to identify four covarying tau PET patterns in amyloid-positive individuals with symptomatic Alzheimer\u2019s disease (AD) from the Amsterdam Dementia Cohort (ADC,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200993, mean age\u2009=\u200965.3). The four latent tau spatial patterns identified via LDA were designated as follows: Limbic (Factor 1), characterized by predominant involvement of the limbic regions; Left TPC (Factor 2), centered on the left temporo-parietal cortex (TPC); Posterior (Factor 3), reflecting a posterior neocortical distribution; and MTL-sparing (Factor 4), showing relative sparing of limbic regions with diffuse neocortical tau deposition. Associations between individual loadings on each of these factors and cognitive domain scores were assessed using linear regression analyses. We then applied the ADC-derived model to an independent validation sample from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009162, mean age\u2009=\u200972.7) to extract individual factor loadings. Associations between factor loadings and contemporaneous cognitive performance were again tested using linear regression, and linear mixed-effects models were used to additionally explore associations with cognitive decline. All analyses were adjusted for age, sex, education, and clinical diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In both the discovery and validation cohort, we identified distinct associations between tau factor loadings and cognitive performance. Higher loading on Factor 1: limbic tau was generally associated with relatively better baseline cognition and slower cognitive decline. Factor 2: left TPC tau was linked to worse baseline scores and faster decline in memory, MMSE and language scores but only in the ADNI cohort. Factor 3: posterior tau was associated with worse baseline MMSE in the ADC cohort and to worse visuospatial performance both cross-sectionally and longitudinally in the ADNI cohort. Factor 4: MTL-sparing tau was related to better longitudinal memory in the ADNI cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This data-driven approach identified overlapping tau patterns that relate to distinct cognitive domains. The findings highlight the value of continuous factor modeling in understanding heterogeneity in Alzheimer\u2019s disease. Such a refinement of quantifying tau heterogeneity may improve patient stratification, refine prognostic accuracy, and ultimately guide the development of individualized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-07868-5","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T07:06:34Z","timestamp":1774940794000},"page":"4664-4676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bayesian modelling demonstrates clinically relevant heterogeneity in Tau PET patterns in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"53","author":[{"given":"Ye","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges El","family":"Fakhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas J.","family":"Guehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsmarieke","family":"van de Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma C.","family":"Coomans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande A.L.","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5802-6946","authenticated-orcid":false,"given":"Colin","family":"Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"7868_CR1","doi-asserted-by":"publisher","unstructured":"Brier MR, Gordon B, Friedrichsen K, et al. Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Sci Transl Med. 2016;8(338). https:\/\/doi.org\/10.1126\/scitranslmed.aaf2362.","DOI":"10.1126\/scitranslmed.aaf2362"},{"issue":"4","key":"7868_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"7868_CR3","doi-asserted-by":"publisher","first-page":"e14338","DOI":"10.1002\/alz.14338","volume":"21","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Knopman DS, Arbizu J, et al. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 2025;21(1):e14338. https:\/\/doi.org\/10.1002\/alz.14338.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"7868_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early A lzheimer disease. Ann Neurol. 2016;79(1):110\u20139. https:\/\/doi.org\/10.1002\/ana.24546.","journal-title":"Ann Neurol"},{"issue":"5","key":"7868_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll M, Lockhart SN, Schonhaut DR, et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016;89(5):971\u201382. https:\/\/doi.org\/10.1016\/j.neuron.2016.01.028.","journal-title":"Neuron"},{"issue":"5","key":"7868_CR6","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139(5):1551\u201367. https:\/\/doi.org\/10.1093\/brain\/aww027.","journal-title":"Brain"},{"issue":"524","key":"7868_CR7","doi-asserted-by":"publisher","first-page":"eaau5732","DOI":"10.1126\/scitranslmed.aau5732","volume":"12","author":"R La Joie","year":"2020","unstructured":"La Joie R, Visani AV, Baker SL, et al. Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12(524):eaau5732. https:\/\/doi.org\/10.1126\/scitranslmed.aau5732.","journal-title":"Sci Transl Med"},{"issue":"3","key":"7868_CR8","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1523\/JNEUROSCI.2028-17.2017","volume":"38","author":"A Maass","year":"2018","unstructured":"Maass A, Lockhart SN, Harrison TM, et al. Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging. J Neurosci. 2018;38(3):530\u201343. https:\/\/doi.org\/10.1523\/JNEUROSCI.2028-17.2017.","journal-title":"J Neurosci"},{"issue":"6","key":"7868_CR9","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/ana.26762","volume":"94","author":"G Minogue","year":"2023","unstructured":"Minogue G, Kawles A, Zouridakis A, et al. Distinct Patterns of Hippocampal Pathology in Alzheimer\u2019s Disease with Transactive Response DNA-binding Protein 43. Ann Neurol. 2023;94(6):1036\u201347. https:\/\/doi.org\/10.1002\/ana.26762.","journal-title":"Ann Neurol"},{"key":"7868_CR10","doi-asserted-by":"publisher","unstructured":"Younes K, Smith V, Johns E, et al. Temporal tau asymmetry spectrum influences divergent behavior and language patterns in Alzheimer\u2019s disease. Neurology Preprint posted online November. 2023;11. https:\/\/doi.org\/10.1101\/2023.11.10.23296836.","DOI":"10.1101\/2023.11.10.23296836"},{"key":"7868_CR11","doi-asserted-by":"publisher","first-page":"1352822","DOI":"10.3389\/fnins.2024.1352822","volume":"18","author":"JL Whitwell","year":"2024","unstructured":"Whitwell JL. Atypical clinical variants of Alzheimer\u2019s disease: are they really atypical? Front Neurosci. 2024;18:1352822. https:\/\/doi.org\/10.3389\/fnins.2024.1352822.","journal-title":"Front Neurosci"},{"issue":"5","key":"7868_CR12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"the Alzheimer\u2019s Disease Neuroimaging Initiative, Vogel JW, Young AL, et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med. 2021;27(5):871\u201381. https:\/\/doi.org\/10.1038\/s41591-021-01309-6.","journal-title":"Nat Med"},{"key":"7868_CR13","doi-asserted-by":"publisher","first-page":"101823","DOI":"10.1016\/j.nicl.2019.101823","volume":"23","author":"I Sintini","year":"2019","unstructured":"Sintini I, Martin PR, Graff-Radford J, et al. Longitudinal tau-PET uptake and atrophy in atypical Alzheimer\u2019s disease. NeuroImage Clin. 2019;23:101823. https:\/\/doi.org\/10.1016\/j.nicl.2019.101823.","journal-title":"NeuroImage Clin"},{"issue":"9","key":"7868_CR14","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1093\/brain\/awv191","volume":"138","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Pijnenburg YAL, Perry DC, et al. The behavioural\/dysexecutive variant of Alzheimer\u2019s disease: clinical, neuroimaging and pathological features. Brain. 2015;138(9):2732\u201349. https:\/\/doi.org\/10.1093\/brain\/awv191.","journal-title":"Brain"},{"issue":"2","key":"7868_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jalz.2019.08.201","volume":"16","author":"R Ossenkoppele","year":"2020","unstructured":"Ossenkoppele R, Lyoo CH, Sudre CH, et al. Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer\u2019s disease. Alzheimers Dement. 2020;16(2):335\u201344. https:\/\/doi.org\/10.1016\/j.jalz.2019.08.201.","journal-title":"Alzheimers Dement"},{"key":"7868_CR16","doi-asserted-by":"publisher","unstructured":"Groot C, Yeo BTT, Vogel JW, et al. Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. Neurology. 2020;95(12). https:\/\/doi.org\/10.1212\/WNL.0000000000010362.","DOI":"10.1212\/WNL.0000000000010362"},{"key":"7868_CR17","doi-asserted-by":"publisher","unstructured":"Zhang X, Mormino EC, Sun N, et al. Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer\u2019s disease. Proc Natl Acad Sci. 2016;113(42). https:\/\/doi.org\/10.1073\/pnas.1611073113.","DOI":"10.1073\/pnas.1611073113"},{"issue":"3","key":"7868_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM Van Der Flier","year":"2018","unstructured":"Van Der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. J Alzheimer\u2019s Dis. 2018;62(3):1091\u2013111. https:\/\/doi.org\/10.3233\/JAD-170850.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"3","key":"7868_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.008.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"7868_CR20","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20(8):5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"7868_CR21","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","volume":"64","author":"BM Tijms","year":"2018","unstructured":"Tijms BM, Willemse EAJ, Zwan MD, et al. Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-\u03b2 1\u201342 Analysis Results. Clin Chem. 2018;64(3):576\u201385. https:\/\/doi.org\/10.1373\/clinchem.2017.281055.","journal-title":"Clin Chem"},{"issue":"1","key":"7868_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.dadm.2018.08.006","volume":"10","author":"EAJ Willemse","year":"2018","unstructured":"Willemse EAJ, Van Maurik IS, Tijms BM, et al. Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer\u2019s disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimers Dement Diagn Assess Dis Monit. 2018;10(1):563\u201372. https:\/\/doi.org\/10.1016\/j.dadm.2018.08.006.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"issue":"4","key":"7868_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82(4):239\u201359. https:\/\/doi.org\/10.1007\/BF00308809.","journal-title":"Acta Neuropathol (Berl)"},{"issue":"11","key":"7868_CR24","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28(11):2381\u20137. https:\/\/doi.org\/10.1038\/s41591-022-02049-x.","journal-title":"Nat Med"},{"issue":"1","key":"7868_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"for the Alzheimer\u2019s Disease Neuroimaging Initiative, Royse SK, Minhas DS, et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther. 2021;13(1):99. https:\/\/doi.org\/10.1186\/s13195-021-00836-1.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"7868_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11682-012-9186-z","volume":"6","author":"PK Crane","year":"2012","unstructured":"for the Alzheimer\u2019s Disease Neuroimaging Initiative, Crane PK, Carle A, et al. Development and assessment of a composite score for memory in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012;6(4):502\u201316. https:\/\/doi.org\/10.1007\/s11682-012-9186-z.","journal-title":"Brain Imaging Behav"},{"issue":"4","key":"7868_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11682-012-9176-1","volume":"6","author":"LE Gibbons","year":"2012","unstructured":"for the Alzheimer\u2019s Disease Neuroimaging Initiative, Gibbons LE, Carle AC, et al. A composite score for executive functioning, validated in Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6(4):517\u201327. https:\/\/doi.org\/10.1007\/s11682-012-9176-1.","journal-title":"Brain Imaging Behav"},{"issue":"1","key":"7868_CR28","doi-asserted-by":"publisher","first-page":"e12072","DOI":"10.1002\/trc2.12072","volume":"6","author":"S Choi","year":"2020","unstructured":"Choi S, Mukherjee S, Gibbons LE, et al. Development and validation of language and visuospatial composite scores in ADNI. Alzheimers Dement Transl Res Clin Interv. 2020;6(1):e12072. https:\/\/doi.org\/10.1002\/trc2.12072.","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"issue":"8","key":"7868_CR29","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy A, Smith R, Ossenkoppele R, et al. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurol. 2020;77(8):955. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0989.","journal-title":"JAMA Neurol"},{"issue":"1","key":"7868_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-019-0510-3","volume":"11","author":"T Timmers","year":"2019","unstructured":"Timmers T, Ossenkoppele R, Wolters EE, et al. Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer\u2019s disease spectrum. Alzheimers Res Ther. 2019;11(1):60. https:\/\/doi.org\/10.1186\/s13195-019-0510-3.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"7868_CR31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hbm.10123","volume":"19","author":"A Hammers","year":"2003","unstructured":"Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224\u201347. https:\/\/doi.org\/10.1002\/hbm.10123.","journal-title":"Hum Brain Mapp"},{"issue":"4","key":"7868_CR32","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.neuroimage.2004.10.017","volume":"24","author":"C Svarer","year":"2005","unstructured":"Svarer C, Madsen K, Hasselbalch SG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. NeuroImage. 2005;24(4):969\u201379. https:\/\/doi.org\/10.1016\/j.neuroimage.2004.10.017.","journal-title":"NeuroImage"},{"issue":"1","key":"7868_CR33","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1038\/s41598-020-57951-6","volume":"10","author":"SN Yaakub","year":"2020","unstructured":"Yaakub SN, Heckemann RA, Keller SS, McGinnity CJ, Weber B, Hammers A. On brain atlas choice and automatic segmentation methods: a comparison of MAPER & FreeSurfer using three atlas databases. Sci Rep. 2020;10(1):2837. https:\/\/doi.org\/10.1038\/s41598-020-57951-6.","journal-title":"Sci Rep"},{"issue":"1","key":"7868_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13195-021-00772-0","volume":"13","author":"EM Coomans","year":"2021","unstructured":"Coomans EM, Schoonhoven DN, Tuncel H, et al. In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimers Res Ther. 2021;13(1):35. https:\/\/doi.org\/10.1186\/s13195-021-00772-0.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"7868_CR35","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R, Rabinovici GD, Smith R, et al. Discriminative Accuracy of [18 F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2018;320(11):1151. https:\/\/doi.org\/10.1001\/jama.2018.12917.","journal-title":"JAMA"},{"issue":"5","key":"7868_CR36","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/brain\/awy059","volume":"141","author":"CR Jack","year":"2018","unstructured":"Jack CR, Wiste HJ, Schwarz CG, et al. Longitudinal tau PET in ageing and Alzheimer\u2019s disease. Brain. 2018;141(5):1517\u201328. https:\/\/doi.org\/10.1093\/brain\/awy059.","journal-title":"Brain"},{"key":"7868_CR37","doi-asserted-by":"publisher","unstructured":"Zhang X, Mormino EC, Sun N, et al. Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer\u2019s disease. Proc Natl Acad Sci. 2016;113(42). https:\/\/doi.org\/10.1073\/pnas.1611073113.","DOI":"10.1073\/pnas.1611073113"},{"issue":"4","key":"7868_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82(4):239\u201359. https:\/\/doi.org\/10.1007\/BF00308809.","journal-title":"Acta Neuropathol (Berl)"},{"issue":"8","key":"7868_CR39","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1136\/jnnp-2020-325497","volume":"92","author":"E Singleton","year":"2021","unstructured":"Singleton E, Hansson O, Pijnenburg YAL, et al. Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2021;92(8):872\u201380. https:\/\/doi.org\/10.1136\/jnnp-2020-325497.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7868_CR40","doi-asserted-by":"publisher","first-page":"116043","DOI":"10.1016\/j.neuroimage.2019.116043","volume":"201","author":"N Sun","year":"2019","unstructured":"Sun N, Mormino EC, Chen J, Sabuncu MR, Yeo BTT. Multi-modal latent factor exploration of atrophy, cognitive and tau heterogeneity in Alzheimer\u2019s disease. NeuroImage. 2019;201:116043. https:\/\/doi.org\/10.1016\/j.neuroimage.2019.116043.","journal-title":"NeuroImage"},{"key":"7868_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fnagi.2019.00211","volume":"11","author":"S Jeon","year":"2019","unstructured":"Jeon S, Kang JM, Seo S, et al. Topographical Heterogeneity of Alzheimer\u2019s Disease Based on MR Imaging, Tau PET, and Amyloid PET. Front Aging Neurosci. 2019;11:211. https:\/\/doi.org\/10.3389\/fnagi.2019.00211.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"7868_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"the Alzheimer\u2019s Disease Neuroimaging Initiative, Vogel JW, Young AL, et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med. 2021;27(5):871\u201381. https:\/\/doi.org\/10.1038\/s41591-021-01309-6.","journal-title":"Nat Med"},{"issue":"5","key":"7868_CR43","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"the Alzheimer\u2019s Disease Neuroimaging Initiative, Vogel JW, Young AL, et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med. 2021;27(5):871\u201381. https:\/\/doi.org\/10.1038\/s41591-021-01309-6.","journal-title":"Nat Med"},{"key":"7868_CR44","unstructured":"Oxtoby NP, Young AL, Cash DM et al. Data-driven models of dominantly-inherited Alzheimer\u2019s disease progression."},{"key":"7868_CR45","doi-asserted-by":"publisher","unstructured":"Yue J, Shi Y et al. Uncovering Heterogeneity in Alzheimer\u2019s Disease from Graphical Modeling of the Tau Spatiotemporal Topography. In: Greenspan H, Madabhushi A, Mousavi P, eds. Medical Image Computing and Computer Assisted Intervention \u2013 MICCAI 2023. Vol 14224. Lecture Notes in Computer Science. Springer Nature Switzerland; 2023:262\u2013271. https:\/\/doi.org\/10.1007\/978-3-031-43904-9_26","DOI":"10.1007\/978-3-031-43904-9_26"},{"issue":"1","key":"7868_CR46","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41598-020-57785-2","volume":"10","author":"A Mitelpunkt","year":"2020","unstructured":"Mitelpunkt A, Galili T, Kozlovski T, et al. Novel Alzheimer\u2019s disease subtypes identified using a data and knowledge driven strategy. Sci Rep. 2020;10(1):1327. https:\/\/doi.org\/10.1038\/s41598-020-57785-2.","journal-title":"Sci Rep"},{"issue":"5","key":"7868_CR47","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Sch\u00f6ll M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139(5):1551\u201367. https:\/\/doi.org\/10.1093\/brain\/aww027.","journal-title":"Brain"},{"key":"7868_CR48","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fneur.2019.00524","volume":"10","author":"D Ferreira","year":"2019","unstructured":"Ferreira D, Pereira JB, Volpe G, Westman E. Subtypes of Alzheimer\u2019s Disease Display Distinct Network Abnormalities Extending Beyond Their Pattern of Brain Atrophy. Front Neurol. 2019;10:524. https:\/\/doi.org\/10.3389\/fneur.2019.00524.","journal-title":"Front Neurol"},{"issue":"2","key":"7868_CR49","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jalz.2019.08.201","volume":"16","author":"R Ossenkoppele","year":"2020","unstructured":"Ossenkoppele R, Lyoo CH, Sudre CH, et al. Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer\u2019s disease. Alzheimers Dement. 2020;16(2):335\u201344. https:\/\/doi.org\/10.1016\/j.jalz.2019.08.201.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"7868_CR50","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jagp.2024.03.009","volume":"32","author":"DR Lee","year":"2024","unstructured":"Lee DR, Romero T, Serrano KS, et al. Demographics, Symptoms, Psychotropic Use, and Caregiver Distress in Patients With Early vs Late Onset Dementia. Am J Geriatr Psychiatry. 2024;32(8):944\u201354. https:\/\/doi.org\/10.1016\/j.jagp.2024.03.009.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"7868_CR51","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00259-021-05669-6","volume":"49","author":"D Visser","year":"2022","unstructured":"Visser D, Verfaillie SCJ, Wolters EE, et al. Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2022;49(6):1951\u201363. https:\/\/doi.org\/10.1007\/s00259-021-05669-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7868_CR52","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"the Alzheimer\u2019s Disease Neuroimaging Initiative, Vogel JW, Young AL, et al. Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med. 2021;27(5):871\u201381. https:\/\/doi.org\/10.1038\/s41591-021-01309-6.","journal-title":"Nat Med"},{"issue":"6","key":"7868_CR53","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaneurol.2018.0395","volume":"75","author":"ZA Miller","year":"2018","unstructured":"Miller ZA, Rosenberg L, Santos-Santos MA, et al. Prevalence of Mathematical and Visuospatial Learning Disabilities in Patients With Posterior Cortical Atrophy. JAMA Neurol. 2018;75(6):728\u201337. https:\/\/doi.org\/10.1001\/jamaneurol.2018.0395.","journal-title":"JAMA Neurol"},{"issue":"4","key":"7868_CR54","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault J, Benedet AL, Pascoal TA, et al. Association of Apolipoprotein E \u03b54 With Medial Temporal Tau Independent of Amyloid-\u03b2. JAMA Neurol. 2020;77(4):470. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4421.","journal-title":"JAMA Neurol"},{"issue":"7","key":"7868_CR55","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00259-020-05099-w","volume":"48","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Leuzy A, Cho H, et al. The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Eur J Nucl Med Mol Imaging. 2021;48(7):2245\u201358. https:\/\/doi.org\/10.1007\/s00259-020-05099-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7868_CR56","doi-asserted-by":"publisher","unstructured":"La Joie R, Visani AV, Lesman-Segev OH, et al. Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. Neurology. 2021;96(5). https:\/\/doi.org\/10.1212\/WNL.0000000000011270.","DOI":"10.1212\/WNL.0000000000011270"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07868-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07868-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07868-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:13:05Z","timestamp":1781644385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07868-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7868"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07868-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and was approved by the medical ethics review committee of the Amsterdam University Medical Center for ADC, and the local institutional review boards for ADNI. Written informed consent was obtained from all participants or their assigned surrogate decision-makers prior to cohort enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"K.J., G.F., N.G., Y.X. report no competing interests. C.G., Y.P. report no competing interests. E.vd.G. has performed contract research for Heuron Inc., AC Immune, and Roche. EvdG has a consultancy agreement with IXICO and Life Molecular Imaging for reading PET scans. All funding is paid to her institution. R.O. is currently a full-time employee of Eli Lilly and Company. His contribution to the work presented in this manuscript was performed as an employee of Amsterdam University Medical Centers. R.O. has received research funding\/support from European Research Council, ZonMw, NWO, National Institute of Health, Alzheimer Association, Alzheimer Nederland, Stichting Dioraphte, Cure Alzheimer\u2019s fund, Health Holland, ERA PerMed, Alzheimerfonden, Hjarnfonden, Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics, has given lectures in symposia sponsored by GE Healthcare, received speaker fees from Springer, and was an advisory board\/steering committee member for Asceneuron, Biogen, Johnson & Johnson and Bristol Myers Squibb. All the aforementioned has been paid to Amsterdam University Medical Centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}